Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26).
Item | Description | The company |
---|---|---|
FCFF | Free cash flow to the firm is the cash flow available to the Medtronic PLC suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. | Medtronic PLC FCFF decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level. |
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26).
2 2024 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= 826 × 23.40% = 193
Enterprise Value to FCFF Ratio, Current
Selected Financial Data (US$ in millions) | |
Enterprise value (EV) | 124,398) |
Free cash flow to the firm (FCFF) | 5,833) |
Valuation Ratio | |
EV/FCFF | 21.33 |
Benchmarks | |
EV/FCFF, Competitors1 | |
Abbott Laboratories | 36.95 |
Cigna Group | 9.43 |
CVS Health Corp. | 9.81 |
Elevance Health Inc. | 10.48 |
Humana Inc. | 7.23 |
Intuitive Surgical Inc. | 248.83 |
UnitedHealth Group Inc. | 19.75 |
EV/FCFF, Sector | |
Health Care Equipment & Services | 18.94 |
EV/FCFF, Industry | |
Health Care | 24.16 |
Based on: 10-K (reporting date: 2024-04-26).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | ||
---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||
Enterprise value (EV)1 | 120,025) | 132,878) | 131,529) | 183,640) | 139,945) | 148,881) | |
Free cash flow to the firm (FCFF)2 | 5,833) | 5,007) | 6,473) | 5,427) | 6,529) | 6,746) | |
Valuation Ratio | |||||||
EV/FCFF3 | 20.58 | 26.54 | 20.32 | 33.84 | 21.43 | 22.07 | |
Benchmarks | |||||||
EV/FCFF, Competitors4 | |||||||
Abbott Laboratories | — | 36.51 | 23.24 | 23.47 | 36.94 | 33.05 | |
Cigna Group | — | 10.44 | 13.38 | 14.17 | 9.16 | 10.24 | |
CVS Health Corp. | — | 11.96 | 10.00 | 10.30 | 9.42 | 12.30 | |
Elevance Health Inc. | — | 14.19 | 13.32 | 12.74 | 6.04 | 12.73 | |
Humana Inc. | — | 9.95 | 14.88 | 42.03 | 7.92 | 8.46 | |
Intuitive Surgical Inc. | — | 170.92 | 85.45 | 56.01 | 76.70 | 54.58 | |
UnitedHealth Group Inc. | — | 17.59 | 19.30 | 22.21 | 15.82 | 17.51 | |
EV/FCFF, Sector | |||||||
Health Care Equipment & Services | — | 18.44 | 17.28 | 19.60 | 14.85 | 16.66 | |
EV/FCFF, Industry | |||||||
Health Care | — | 24.38 | 17.63 | 16.41 | 17.93 | 18.26 |
Based on: 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26).
3 2024 Calculation
EV/FCFF = EV ÷ FCFF
= 120,025 ÷ 5,833 = 20.58
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/FCFF | Enterprise value to free cash flow to the firm is whole company valuation indicator. | Medtronic PLC EV/FCFF ratio increased from 2022 to 2023 but then slightly decreased from 2023 to 2024 not reaching 2022 level. |